Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

64.41
-0.2800-0.43%
Pre-market: 64.38-0.0325-0.05%07:08 EDT
Volume:6.57M
Turnover:423.82M
Market Cap:131.12B
PE:14.18
High:65.05
Open:64.57
Low:64.26
Close:64.69
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.93
T/O Rate:0.32%
Dividend:2.51
Dividend Rate:3.90%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.87
PE(LYR):18.62

Loading ...

Bristol Myers Squibb Stock (BMY) Looks Healthier After Ditching Blood Cancer Partner

TIPRANKS
·
Aug 26

Bristol Myers Ends Blood Cancer Drug Deal with Cell Therapy Maker Cellares

Reuters
·
Aug 26

Confirm That We Have Ended Our Partnership with Cellares. - Bristol Myers Spokesperson

THOMSON REUTERS
·
Aug 25

Bristol Myers Spokesperson: Determined Cellares-Partnered Cell Shuttle System Could not Meet Necessary Requirements to Make Commercial Breyanzi

THOMSON REUTERS
·
Aug 25

Bristol-Myers Squibb Adds Early Alzheimer’s Antibody To Its Long-Term Growth Story

TIPRANKS
·
Aug 22

Movement Alert|Bristol-Myers Squibb Rises 3.02% in Regular Trading, AI Antibody R&D Partnership and Sector Strength Fuel Rally

Market Focus
·
Aug 21

Bristol Myers Squibb Co. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Aug 21

Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement

TradingKey
·
Aug 21

Movement Alert|Bristol-Myers Squibb Falls 3.03% in Regular Trading, Pharmaceutical Sector Broadly Under Pressure

Market Focus
·
Aug 21

Bristol‑Myers Squibb Advances Navlimetostat Metabolism Study, Signaling Steady Pipeline Progress

TIPRANKS
·
Aug 21

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

Chai Discovery Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

Reuters
·
Aug 20

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 20

Movement Alert|Bristol-Myers Squibb Rises 3.11% in Regular Trading, Zenbexus Gains FDA Accelerated Approval as Pharma Sector Rallies

Market Focus
·
Aug 19

Hengrui Pharma FY26 H1 Profit Attributable to Owners Rises 0.3% to RMB 4.47 Billion; Revenue Falls 1.9% to RMB 15.46 Billion

Reuters
·
Aug 19

The Key to Pharma M&A: Never Shopping Hungry - Heard on the Street

Dow Jones
·
Aug 19

Lytix Biopharma Names Timothy Herpin Chief Business Officer

Reuters
·
Aug 18

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 18

AstraZeneca Suffers Another Setback as it Halts Volrustomig Lung Cancer Trial

Reuters
·
Aug 17

How First CELMoD MRD-Based Approval in Myeloma At Bristol Myers Squibb (BMY) Has Changed Its Investment Story

Simply Wall St.
·
Aug 15